Several molecular events, such as TMPRSS2-ERG fusion, Bcl-2 overexpression, as well as PTEN loss has been described as major biomarkers of PCa aggressiveness and therapy response [35–38]. The gene discussed is ERG; the disease is posterior cortical atrophy.